跳至主要内容
临床试验/NL-OMON56091
NL-OMON56091尚未招募2 期

A FEASIBILITY STUDY OF SGM-101, A FLUOROCHROME-LABELED ANTI-CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY FOR THE INTRAOPERATIVE DETECTION OF COLORECTAL BRAIN METASTASES - SGM-101 in colorectal brain metastases

eids Universitair Medisch Centrum0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Signed informed consent prior to any study-mandated procedure;
  • 2. Patients aged over 18 years old;
  • 3. All women of child bearing potential and all males must practice effective
  • contraception during the study and be willing and able to continue
  • contraception for at least 30 days after their last dose of study treatment.
  • 4. Has the ability to communicate well with the Investigator in the Dutch
  • language and willing to comply with the study restrictions.
  • 5. Diagnosed with brain metastasis of colorectal origin and scheduled for a

排除标准

  • 6. History of any anaphylactic reaction;
  • 7. Previous use of SGM-101;
  • 8. Other malignancies either currently active or diagnosed in the last 5 years,
  • except adequately treated in situ carcinoma of the cervix and basal or squamous
  • cell skin carcinoma;
  • 9. Patients pregnant or breastfeeding (pregnancy should be ruled out by a
  • pregnancy test within two weeks prior to administration of the conjugate);
  • 10. Any condition that the investigator considers to be potentially
  • jeopardizing the patient*s well-being or the study objectives (following a
  • detailed medical history, physical examination, vital signs (systolic and
  • diastolic blood pressure, pulse rate, body temperature) and 12-lead
  • electrocardiogram (ECG)). Minor deviations from the normal range may be
  • accepted, if judged by the Investigator to have no clinical relevance.

研究者

相似试验

A FEASIBILITY STUDY OF SGM-101, A... | 临床试验